DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
ConveyMED is an Ed Tech Marketplace and the first podcast platform designed specifically for Professional Education. Busy physicians, nurses, pharmacists and other professionals want...
Clint McGill is addressing one of the biggest challenge in youth sports - building mental toughness. As a former high level baseball player himself,...
Mark Cherney is the Founder and Executive Chairman of both US Urology Partners and Prologics. This past year Mark transitioned from the CEO role...
